Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan
Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan
复制标题
日本神经氨酸酶突变和神经氨酸酶抑制剂耐药性的连续流感监测
DOI：
10.1111/irv.12624
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
H.
中科院分区：
文献类型：
--
作者：
Chong;Y.;Matsumoto;S.;Kang;D.;Ikematsu;H.
背景：用于治疗流感病毒感染的神经氨酸酶抑制剂（NAIs）的大量消耗使日本面临成为耐NAI病毒全球传播中心的风险。目的了解日本流行性流感病毒NA氨基酸突变及其与NAI耐药性的关系。方法收集2011 - 2012年至2016 - 2017年日本流感流行季共1791份样本，其中A/H1N1pdm09株396株、A/H3N2株1117株、B株278株，采用奥司他韦、扎那米韦、帕拉米韦和拉尼那米韦等抗感染药物测定其50%抑菌浓度（IC50）值。然后对其中49株A/H1N1pdm09、251株A/H3N2和80株B进行NA全基因测序。结果在流行季节检测到耐神经氨酸酶抑制剂A/H1N1pdm09病毒，检出率为1.3%（5/396株）。在6个季节中，A/H3N2和B病毒均未对这4种NAIs产生耐药性。在A/H1N1pdm09和A/H3N2病毒的NA催化位点分别检测到5个和13个AA突变。B病毒的催化位点未见突变。A/H1N1pdm09催化位点的5个突变位点中有4个包含H275Y，这与对奥司他韦和帕拉米韦的高耐药有关。A/H3N2中大多数（10/13）的催化位点突变与MDCK传代诱导（D151G/N）有关。最后，在检测的A/H3N2和B病毒中未检测到与NAI抗性相关的突变。结论流感病毒NA催化位点保存完好。即使在日本，也没有观察到耐NAI病毒的传播，携带H275Y的A/H1N1pdm09病毒仍然有限。
BackgroundThe large consumption of neuraminidase inhibitors (NAIs) for the treatment of influenza virus infections places Japan at risk of becoming the epicenter of the global spread of NAI‐resistant viruses.ObjectiveTo clarify NA amino acid mutations of epidemic influenza viruses in Japan and their related NAI resistance.MethodsA total of 1791 samples, including 396 A/H1N1pdm09, 1117 A/H3N2, and 278 B isolates, were collected to determine of their 50% inhibitory concentration (IC50) values by NAIs (oseltamivir, zanamivir, peramivir, and laninamivir) during the Japanese seasons from 2011‐2012 to 2016‐2017. Then, 380 samples including 49 A/H1N1pdm09, 251 A/H3N2, and 80 B isolates were sequenced for the entire NA genes.ResultsNeuraminidase inhibitor‐resistant A/H1N1pdm09 viruses were detected at a frequency of 1.3% (5/396 isolates) in the epidemic seasons. None of the A/H3N2 and B viruses developed resistance to any of the four NAIs during the six seasons. Only five and 13 AA mutations were detected in the NA catalytic sites of A/H1N1pdm09 and A/H3N2 viruses, respectively. No mutations were observed in the catalytic sites of B viruses. Four of the five mutations in the catalytic sites of A/H1N1pdm09 consisted of H275Y, which was related to high resistance to oseltamivir and peramivir. Most (10/13) of the catalytic site mutations in A/H3N2 were associated with MDCK‐passaged induction (D151G/N). Finally, no mutations related to substantial NAI resistance were detected in the A/H3N2 and B viruses examined.ConclusionThese findings suggest that the NA catalytic sites of influenza viruses are well preserved. Even in Japan, no spread of NAI‐resistant viruses has been observed, and A/H1N1pdm09 viruses carrying H275Y remain limited.
登录
查看更多内容
四种神经氨酸酶抑制剂对日本 2013-2014 季节流行的流感病毒临床分离株的体外神经氨酸酶抑制活性。
DOI：
10.1016/j.jiac.2015.05.004
发表时间：
2015
期刊：
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
影响因子：
--
作者：
H. Ikematsu;Naoki Kawai;N. Iwaki;S. Kashiwagi
通讯作者：
S. Kashiwagi
2008-2009年亚洲安全
DOI：
--
发表时间：
2008
期刊：
影响因子：
--
作者：
坪郷實;編;西澤 由隆;西澤 由隆;Yoshitaka Nishizawa (with Koichi Kuriyama);西澤 由隆;Yoshitaka Nishizawa;西澤 由隆;小堀 眞裕;小堀 眞裕;小堀眞裕;梅川正美他編著(小堀眞裕);Muneyuki Shindo;Ken Ishida;笹倉宏紀;Hiroki Sasakura;Noboru Sekiya;笹倉 宏紀;石田憲;Ken Ishida;石田 憲;新藤宗幸;石田 憲;新藤 宗幸;石田 憲;関谷 昇;関谷 昇;永野隆行;堀 芳枝;永野 隆行;上村 英明;永野隆行;堀芳枝;堀芳枝;永野隆行;永野隆行;永野隆行;Rieko Karatani;上村英明;柄谷利恵子;柄谷利恵子;柄谷利恵子;永野隆行;上村英明;上村英明;永野隆行
通讯作者：
永野隆行
影响因子：
3.7
作者：
Lee HK;Tang JW;Kong DH;Loh TP;Chiang DK;Lam TT;Koay ES
通讯作者：
Koay ES
四种神经氨酸酶抑制剂对日本2012-2013季流感病毒临床分离株的体外神经氨酸酶抑制活性。
DOI：
10.1016/j.jiac.2014.08.030
发表时间：
2015
期刊：
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
影响因子：
--
作者：
H. Ikematsu;Naoki Kawai;N. Iwaki;S. Kashiwagi
通讯作者：
S. Kashiwagi
影响因子：
9.4
作者：
Stockton, J;Ellis, JS;Zambon, MC
通讯作者：
Zambon, MC